Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Value · Victory Capital

Victory RS Value Fund Class A (RSVAX)

Ticker RSVAX · · Holdings as of Jun 30, 2026

Expense ratio
1.3%$130/yr per $10k
5-yr return
+8.1%annualized
1-yr return
−1.4%as of Dec 2025
Net assets
$253.5Mall share classes
Holdings
61

Bottom line

Is RSVAX a good fund? The bottom line

RSVAX is the Class A share class of Victory RS Value Fund, a managed large value mutual fund from Victory Capital.

It charges 1.3% — about $130 a year on every $10,000 invested, more expensive than 83% of large value funds we track.

It returned −1.4% over one year, +8.1% a year over five years, +8.2% a year over ten (as of Dec 31, 2025, per its prospectus).

With $253 million in net assets and 61 holdings, its largest position is Globe Life Inc. (4.4%) and the top 10 make up 26.8% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.3%)
  • 5-year return in the bottom quarter of its category
  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What RSVAX invests in

The Victory RS Value Fund (the Fund) seeks to provide long-term capital appreciation.

The Adviser pursues the Funds investment objective by investing, under normal circumstances, principally in equity securities of companies with market capitalizations between $1 billion and 120% of the market capitalization of the largest company included in the Russell Midcap Index (Index) (currently, approximately $139.8 billion, based on the size of the largest company in the Index on March 31, 2026) that the Adviser believes are undervalued. The size of companies in the Index changes with market conditions and the composition of the Index. The Fund typically invests in equity securities of U.S. companies but may also invest any portion of its assets in foreign securities, including depositary receipts such as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The Fund holds a relatively few number of securities; and as a result of the Advisers investment…

From the fund's prospectus (filed Apr 29, 2026).

RSVAX performance

Fund calendar-year total returns, 2016–2025 2016: +10.9%; 2017: +17.4%; 2018: −10.8%; 2019: +31.4%; 2020: −2.6%; 2021: +27.3%; 2022: −3.0%; 2023: +7.5%; 2024: +12.6%; 2025: +4.7% +11% 2016 +17% 2017 −11% 2018 +31% 2019 −3% 2020 +27% 2021 −3% 2022 +8% 2023 +13% 2024 +5% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
RSVAX−1.4%+8.1%+8.2%
Large Value median+13.6%+11.3%+10.2%

Source: Fund prospectus, as of Dec 31, 2025

Full RSVAX performance history →

What RSVAX costs

On a $10,000 investment, RSVAX's 1.3% expense ratio costs about $130 a year. The prospectus estimates $2,082 in total costs over 10 years (assuming 5% annual returns). The median large value fund charges 0.81%.

See the full RSVAX fee table →

RSVAX top 10 holdings

#Holding% of fund
1Globe Life Inc.4.40%
2Teva Pharmaceutical Industries Limited...3.05%
3Firstenergy Corp.2.72%
4Ametek, Inc.2.70%
5Nnn REIT, Inc.2.56%
6Centerpoint Energy, Inc.2.44%
7Dover Corporation2.37%
8Marketaxess Holdings Inc.2.21%
9The Timken Company2.20%
10Littelfuse, Inc.2.13%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 26.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to RSVAX

More funds like RSVAX →

RSVAX FAQ

What is the expense ratio of RSVAX?
RSVAX's expense ratio is 1.3%, which works out to about $130 a year for every $10,000 invested. The prospectus estimates total costs of $2,082 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is RSVAX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.3%); 5-year return in the bottom quarter of its category; front-end sales load up to 5.75%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does RSVAX hold?
RSVAX's largest holdings are Globe Life Inc. (4.4%), Teva Pharmaceutical Industries Limited... (3.0%), Firstenergy Corp. (2.7%), Ametek, Inc. (2.7%), Nnn REIT, Inc. (2.6%). It holds 61 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is RSVAX's 5-year return?
RSVAX returned +8.1% a year over the five years ending Dec 31, 2025, and +8.2% a year over ten years. Past performance does not guarantee future results.
Does RSVAX have a sales load?
Yes. RSVAX has a maximum front-end sales charge of 5.75%.
Who manages RSVAX?
RSVAX is offered by Victory Capital through Victory Portfolios.